Tonix Pharmaceuticals Holding Corp (TNXP)
0.1683
+0.01
(+5.19%)
USD |
NASDAQ |
Apr 26, 16:00
0.17
0.00 (0.00%)
After-Hours: 20:00
Tonix Pharmaceuticals Net Income (Quarterly): -27.32M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -27.32M |
| September 30, 2023 | -27.98M |
| June 30, 2023 | -28.36M |
| March 31, 2023 | -33.00M |
| December 31, 2022 | -31.68M |
| September 30, 2022 | -28.98M |
| June 30, 2022 | -23.14M |
| March 31, 2022 | -26.42M |
| December 31, 2021 | -29.55M |
| September 30, 2021 | -18.53M |
| June 30, 2021 | -23.55M |
| March 31, 2021 | -20.65M |
| December 31, 2020 | -17.02M |
| September 30, 2020 | -11.99M |
| June 30, 2020 | -14.18M |
| March 31, 2020 | -7.273M |
| December 31, 2019 | -8.707M |
| September 30, 2019 | -7.838M |
| June 30, 2019 | -5.84M |
| March 31, 2019 | -6.233M |
| December 31, 2018 | -7.588M |
| September 30, 2018 | -5.479M |
| June 30, 2018 | -6.087M |
| March 31, 2018 | -6.935M |
| December 31, 2017 | -5.493M |
| Date | Value |
|---|---|
| September 30, 2017 | -5.786M |
| June 30, 2017 | -4.78M |
| March 31, 2017 | -5.064M |
| December 31, 2016 | -7.482M |
| September 30, 2016 | -7.578M |
| June 30, 2016 | -9.806M |
| March 31, 2016 | -13.98M |
| December 31, 2015 | -13.36M |
| September 30, 2015 | -13.25M |
| June 30, 2015 | -11.76M |
| March 31, 2015 | -9.681M |
| December 31, 2014 | -8.989M |
| September 30, 2014 | -7.419M |
| June 30, 2014 | -6.044M |
| March 31, 2014 | -5.164M |
| December 31, 2013 | -3.707M |
| September 30, 2013 | -3.09M |
| June 30, 2013 | -2.086M |
| March 31, 2013 | -2.001M |
| December 31, 2012 | -2.629M |
| September 30, 2012 | -1.732M |
| June 30, 2012 | -3.074M |
| March 31, 2012 | -2.015M |
| December 31, 2011 | -1.586M |
| September 30, 2011 | -1.014M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-33.00M
Minimum
Mar 2023
-5.84M
Maximum
Jun 2019
-20.63M
Average
-23.14M
Median
Jun 2022
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals Inc | 45.80M |
| PetVivo Holdings Inc | -1.750M |
| Acurx Pharmaceuticals Inc | -5.115M |
| Kezar Life Sciences Inc | -32.26M |
| Allakos Inc | -62.55M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 3.779M |
| Total Expenses (Quarterly) | 31.11M |
| EPS Diluted (Quarterly) | -0.4661 |
| Enterprise Value | -0.75M |
| Gross Profit Margin (Quarterly) | 37.36% |
| Profit Margin (Quarterly) | -723.0% |
| Earnings Yield | -4.89K% |